Prosecution Insights
Last updated: October 02, 2026

Examiner: CHEN, TSE W

Tech Center 3700 • Art Units: 2116 3736 3777 3791 3793

This examiner grants 55% of resolved cases

Analysis

Tse W. Chen, an examiner in Tech Center 3700 and Art Unit 2116, has 169 resolved cases. The allowance rate is 55.0%, which is a balanced outcome for applicants. The median days to allowance is 1426, reflecting a relatively long period for prosecution. This 1426-day duration is a key metric for planning in Art Unit 2116. The 55.0% rate indicates that a majority of cases are eventually granted.

The interview lift is 25.4%. This indicates that interviews are effective at improving the 55.0% allowance rate. In Tech Center 3700, the 1426-day median pendency is a standard expectation for practitioners. The 169 resolved cases provide a reliable statistical profile for this examiner. The 25.4% lift suggests that verbal advocacy is a productive way to resolve outstanding issues.

Practitioners should use the 25.4% interview lift to boost their chances beyond the 55.0% baseline. The 1426-day median to allowance is the expected duration for grants. The 169 cases suggest that engagement is a productive strategy for success in Art Unit 2116. Applicants should factor the 25.4% lift into their overall prosecution strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

55.0%
Allow Rate
-15.0% vs TC avg
194
Total Applications
+25.4%
Interview Lift
1426
Avg Prosecution Days
Based on 169 resolved cases, 2023–2026

Rejection Statute Breakdown

7.9%
§101 Eligibility
23.3%
§102 Novelty
48.8%
§103 Obviousness
16.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18915089 SENSING CONFIGURATIONS FOR NON-UNIFORM NEUROSTIMULATION PATTERNS Non-Final OA Boston Scientific Neuromodulation Corporation
17963968 SYSTEMS, DEVICES, AND METHODS FOR COMMUNICATION BETWEEN AN ANALYTE SENSOR AND EXTERNAL DEVICES Non-Final OA ABBOTT DIABETES CARE INC.
17567866 DRUG RELEASE COMPOSITIONS AND METHODS FOR DELIVERY Non-Final OA ABBOTT DIABETES CARE INC.
17664167 Wireless Hemodynamic Sensors and Methods of Using Same Non-Final OA Georgia Tech Research Corporation
17771440 DEVICE AND METHOD OF DETECTING AND CALIBRATING A VOLTAMMETRIC RESPONSE TO IN VIVO BIOCHEMICALS Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17710095 PREGNANCY-RELATED COMPLICATION IDENTIFICATION AND PREDICTION FROM WEARABLE-BASED PHYSIOLOGICAL DATA Final Rejection Oura Health Oy
18296198 REDUCING SENSOR FOREIGN BODY RESPONSE VIA HIGH SURFACE AREA METAL STRUCTURES Final Rejection Medtronic MiniMed, Inc.
18047789 MINIATURIZED IMPLANTABLE ELECTROCHEMICAL SENSOR DEVICES Final Rejection CALIFORNIA INSTITUTE OF TECHNOLOGY
19101490 SYSTEM AND METHOD FOR ACCOUNTING FOR A CONFOUNDING FACTOR IN THE DETERMINATION OF A PHYSIOLOGIC PARAMETER OR CONDITION Non-Final OA Becton, Dickinson and Company
17370173 ERROR CORRECTION TECHNIQUES ON BIO-IMPEDANCE MEASUREMENTS Non-Final OA Analog Devices International Unlimited Company
19034255 BIO-IMPEDANCE MEASUREMENT SYSTEM Non-Final OA Analog Devices, Inc.
17440602 DEVICE, PROCESS AND COMPUTER PROGRAM FOR INFLUENCING THE BREATHING OF A PERSON Final Rejection Drägerwerk AG & Co. KGaA
18042118 yGT ESTIMATION DEVICE, yGT ESTIMATION METHOD, AND COMPUTER PROGRAM Non-Final OA NISSIN FOODS HOLDINGS CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month